Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Organon & Co. due to misleading statements regarding its capital allocation strategy, particularly concerning dividends and debt reduction, which led to significant financial losses for investors [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Organon between October 31, 2024, and April 30, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Organon, with a deadline of July 22, 2025, for investors to seek the role of lead plaintiff [3]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Financial Misrepresentation - Defendants provided misleading information about Organon's commitment to regular quarterly dividends, claiming it was a "1 capital allocation priority" while concealing the prioritization of debt reduction following the acquisition of Dermavant [5]. - The misleading statements resulted in a 70% decrease in the regular quarterly dividend, causing shareholders to purchase securities at artificially inflated prices [5]. Group 3: Market Reaction - Following the revelations about Organon's financial practices, the company's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [6].

Core Viewpoint - A class action has been filed against Organon & Co. for allegedly misleading investors regarding its debt reduction strategy and the prioritization of capital allocation through dividends [1][2]. Allegations - The complaint claims that during the class period, Organon misrepresented its capital allocation strategy, emphasizing dividends as a "1 capital allocation priority" while concealing the importance of its debt reduction strategy post-acquisition of Dermavant [2][3]. - It is alleged that this misrepresentation led to a significant reduction in the regular quarterly dividend by 70% [3]. Impact of Disclosure - The truth about the company's financial strategy was revealed on May 1, 2025, when Organon announced a drastic cut in its dividend payout from $0.28 to $0.02, aimed at recapturing capital [4]. - Following this announcement, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% [4].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - The allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of over 70% in the quarterly dividend payout [4]. - Following the announcement of the reduced dividend from $0.28 to $0.02 on May 1, 2025, Organon's stock price fell by more than 27% [5]. Group 2: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - The company had previously reported optimistic dividend payouts, which were later contradicted by a newly implemented debt reduction strategy following the acquisition of Dermavant Sciences Ltd [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy, particularly concerning its debt reduction efforts and dividend payouts [1][2][3]. Group 1: Allegations and Misleading Information - The complaint claims that during the class period, Organon prioritized its capital allocation strategy through regular quarterly dividends, presenting it as the "1 capital allocation priority" [2]. - It is alleged that while making these positive statements, Organon concealed the high priority of its debt reduction strategy following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [3]. Group 2: Impact of the Announcement - The truth about the company's financial strategy was revealed on May 1, 2025, when Organon announced a significant reduction in its dividend payout from $0.28 to $0.02 to recapture capital [4]. - Following this announcement, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Organon & Co., with options to serve as lead plaintiff or remain an absent class member [5]. - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [6].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were countered by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon prioritized debt reduction, which was not disclosed to investors [4]. Financial Impact - On May 1, 2025, Organon reported its first quarter 2025 financial results, announcing a drastic reduction in its dividend payout from $0.28 to $0.02, which led to a more than 27% drop in the stock price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) between October 31, 2024, to April 30, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Joseph Hauser v. Organon & Co., et al. (Case No. 2:25-cv-05322) has been commenced in the United States District Court for the District of New Jersey ...

SAN DIEGO, May 20, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more ...

We initiate (NYSE: NYSE: OGN ) at Strong Buy w/ $26.4 PT. Organon & Co. is a diversified portfolio of Rx therapies anchored by global leadership in women's health and accelerating biosimilars. Our thesis is supported by a forecasted operational inflection , withMoretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with d ...

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2] Company Overview - Organon is a global healthcare company primarily focused on improving the health of women [2] Recent Developments - On May 1, 2025, Organon announced a dividend cut of approximately 90%, leading to a stock price decline of more than 28% [3]

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) on behalf of Organon stockholders. Our investigation concerns whether Organon has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations o ...